The Pharmacist

JANUARY 15, 2024

First-time buyers made up 45% of pharmacy sales brokered by business property advisor Christie & Co in the last year, it has revealed in its latest annual report. And 55% of pharmacies were sold to independent contractors and regional multiple operators, Christie & Co said. The rise in first-time buyers is almost double the number […] The post Nearly half of pharmacies sold to first-time buyers, reveals broker appeared first on The Pharmacist.

114

114

Pharmaceutical Commerce

JANUARY 15, 2024

FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.

107

107

The Pharmacist

JANUARY 15, 2024

Pharmacies offering the new Hypertension Case-Finding Service need to focus on converting more patients to ambulatory blood pressure monitoring (ABPM), according to a recent webinar by Community Pharmacy England (CPE). The service, relaunched on 1 December 2023, now requires contractors to have an ABPM device as well as their clinic meter. The CPE webinar, which […] The post Pharmacies urged to boost ambulatory blood pressure monitoring appeared first on The Pharmacist.

Community Pharmacies 99

Community Pharmacies 99

pharmaphorum

JANUARY 15, 2024

Researchers at the University of Cambridge and Pfizer have developed an AI-powered approach to make it easier to design and make pharma molecules

Compounding 112

Compounding 112

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

European Pharmaceutical Review

JANUARY 15, 2024

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree ® (vamorolone), as a safer alternative to corticosteroids, for Duchenne muscular dystrophy (DMD). “In addition to its anti-inflammatory efficacy, both the EMA and the MHRA recognise the benefits of treatment with Agamree for bone health and growth,” Dr Shabir Hasham, Chief Medical Officer of Santhera Pharmaceuticals shared.

100

100

Express Pharma

JANUARY 15, 2024

For a decade, SCHOTT has been awarding scholarships for bachelor (B Pharmacy) and master (M Pharmacy) degree pharmacy students in India. The FIOLAX scholarship nominees of 2023 were celebrated recently. Due to the 10-year anniversary of the program, the award ceremony took place as part of a large celebration in Mumbai, which was attended by many alumni from previous years.

Packaging 98

Packaging 98

European Pharmaceutical Review

JANUARY 15, 2024

The natural polymer tara gum polysaccharide ( Caesalpinia spinosa ) has application potential in pharmaceutical drug delivery , according to researchers in Korea. This is mainly due to its benefits such as its biocompatibility, biodegradability, and safety. A biodegradable alternative A study by the researchers, published in Carbohydrate Polymers , suggested that the material could be a natural, environmentally-friendly alternative to petroleum-based polymers such as plastic.

87

87

pharmaphorum

JANUARY 15, 2024

Santhera’s new treatment for Duchenne muscular dystrophy Agamree has been launched in its first market, Germany, following its EU approval last month.

100

100

Outsourcing Pharma

JANUARY 15, 2024

Access to opioids such as fentanyl can lead to abuse but now two companies have signed an agreement to reduce the abuse potential while making sure they are still accessible to those who need them.

80

80

pharmaphorum

JANUARY 15, 2024

MSD’s Keytruda has been cleared by the FDA as the first PD-1 inhibitor for newly diagnosed cervical cancer patients with less severe disease

101

101

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharma Times

JANUARY 15, 2024

CellVoyant’s platform combines AI with live cell imaging

124

124

pharmaphorum

JANUARY 15, 2024

Germany’s IG BCE trade union has pushed back against any break-up of Bayer, claiming it could put thousands of domestic jobs at risk

92

92

Pharma Times

JANUARY 15, 2024

Companies collaborate to launch walk-in pain clinic

121

121

World Pharma News

JANUARY 15, 2024

Researchers have developed a platform that combines automated experiments with AI to predict how chemicals will react with one another, which could accelerate the design process for new drugs. Predicting how molecules will react is vital for the discovery and manufacture of new pharmaceuticals, but historically this has been a trial-and-error process, and the reactions often fail.

79

79

pharmaphorum

JANUARY 15, 2024

True innovation in life sciences is only possible through a connected, pan-European approach Mike.

100

100

Pharmafile

JANUARY 15, 2024

Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of the company’s Denosumab injections (BA6101 and BA1102). The study will take place in Europe, the US and Japan, with a meeting having recently been held in Germany to share results from a phase 1 pharmacokinetic […] The post Boan Biotech completes enrolment for phase 3 study of Denosumab appeared first on Pharmafile.

Biosimilars 63

Biosimilars 63

Outsourcing Pharma

JANUARY 15, 2024

SGD Pharma has announced its goal to become the global market leader in primary pharmaceutical glass packaging.

Packaging 80

Packaging 80

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for PROLENSA Prolensa is a drug marketed by Bausch And Lomb and is included in one NDA. It is available from two suppliers. There are nine… The post New patent expiration for Bausch And drug PROLENSA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Outsourcing Pharma

JANUARY 15, 2024

Cormica Bradford, a division of Cormica says it is proud to announce a significant expansion of its laboratory capabilities.

76

76

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for IGALMI Igalmi is a drug marketed by Bioxcel and is included in one NDA. It is available from one supplier. There are six patents protecting… The post New patent for Bioxcel drug IGALMI appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Outsourcing Pharma

JANUARY 15, 2024

Access to opioids such as fentanyl can lead to abuse but now two companies have signed an agreement to reduce the abuse potential while making sure they are still accessible to those who need them.

59

59

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for LAZANDA Lazanda is a drug marketed by Btcp Pharma and is included in one NDA. There are five patents protecting this drug. This drug has… The post New patent expiration for Btcp Pharma drug LAZANDA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Outsourcing Pharma

JANUARY 15, 2024

Cormica Bradford, a division of Cormica says it is proud to announce a significant expansion of its laboratory capabilities.

73

73

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Sumitomo Pharma and is included in one NDA. It is available from one supplier. There are eight patents… The post New patent for Sumitomo Pharma drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmafile

JANUARY 15, 2024

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. The approval follows data from the phase 3 KEYNOTE-A18 trial, […] The post FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment appeared first on Pharmafi

58

58

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. It is available from one supplier. There are fifty-four… The post New patent for Amicus Therap drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.

59

59

pharmaphorum

JANUARY 15, 2024

Orion buys stake in LegoChem amid pivot to cancer and pain Phil.

97

97

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for LUMIFY Lumify is a drug marketed by Bausch And Lomb Inc and is included in one NDA. It is available from one supplier. There are… The post New patent for Bausch And drug LUMIFY appeared first on DrugPatentWatch - Make Better Decisions.

59

59

pharmaphorum

JANUARY 15, 2024

Artificial intelligence (AI) is transforming the healthcare industry, particularly in decision-making and therapeutic advancements. Learn how AI will revolutionise healthcare and impact future decision-making processes in this informative article.

57

57

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. It is available from one supplier. There are six patents… The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmaceutical Commerce

JANUARY 15, 2024

The group—known as the Innovators' Network—is meant to serve as a link between entrepreneurs, providers, researchers, and payers while they strive to combat cardiovascular disease.

52

52

Pharma in Brief

JANUARY 15, 2024

The Federal Court ( FC ) has refused to overturn a decision of the Patented Medicine Prices Review Board ( PMPRB or Board ) that found that a patent can pertain to a medicine based on “clinical similarities” to the invention—even if the patent does not actually encompass the medicine. The FC concluded that the Board’s decision was reasonable. Background This case concerns Canadian Patent No. 2,478,237 (the 237 Patent ), which relates to the use of adapalene to treat dermatological disorders.

52

52

PharmExec

JANUARY 15, 2024

The FDA issued the 39th overall approval for Keytruda (pembrolizumab), with the latest in combination with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.

52

52

pharmacy mentor

JANUARY 15, 2024

In the ever-evolving industry of healthcare, pharmacies stand at the forefront of a significant transformation. The traditional, manual methodologies of old pharmacies are giving way to a new era of streamlined, digital operations. This transition not only boosts operational efficiency but also expands the range of services and improves patient engagement.

Medical Records 52

Medical Records Data Entry Communication Medication Dispensing 52

PharmExec

JANUARY 15, 2024

Ginkgo Bioworks announces projected total revenue of $250–$260 million for 2023 for large scale data generation and artificial intelligence for biopharma R&D.

52

52